Source-backed half-life profile
Nicotine half-life calculator
Nicotine has a short parent-compound half-life, but behavior, craving, and cotinine context make the page more than a simple countdown.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
What a careful reader should notice first
The chart is useful for parent-nicotine decline, while use pattern and metabolites can carry a different story.
Source angle
Check whether a source is talking about nicotine itself, replacement products, smoking exposure, or metabolites.
Do not use it for
Do not use the page to estimate craving, withdrawal, cessation outcomes, or testing interpretation.
Best next step
Compare with caffeine and stimulant entries, then read detection-window context.
Nicotine: evidence and interpretation notes
Parent nicotine falls faster than its main biomarker
The Benowitz clinical pharmacology review describes an elimination half-life of roughly two hours for nicotine. HalfLifeDB uses that parent-drug value because it is well established and easy to distinguish from cotinine, the longer-lived metabolite commonly used as a biomarker of nicotine exposure.
That distinction prevents a common category error. The page does not use a cotinine timeline to draw a nicotine line, and it does not use the short parent line to estimate how long a biomarker can be measured.
| Evidence source | What it contributes | Important limit |
|---|---|---|
| Benowitz pharmacology review | Absorption, distribution, metabolism, two-hour parent half-life, and biomarker context | It covers several delivery systems and populations rather than one uniform exposure |
| DailyMed nicotine-gum labeling | A regulated oral-mucosal product context | Gum absorption is not interchangeable with inhaled or transdermal delivery |
| PubChem identity record | Compound identity | It does not support dependence or biomarker timing |
Delivery method changes absorption, not the identity of the curve
The review compares nicotine delivery from tobacco and medicinal products and describes substantial differences in absorption rate and concentration pattern. Inhaled delivery, oral-mucosal products, and transdermal systems can reach the circulation on different schedules. A normalized elimination chart starts at 100% and intentionally removes those peak and absorption differences.
Nicotine is metabolized primarily in the liver, with CYP2A6 playing a major role. The review identifies genetic and environmental influences on metabolism, including age, sex, pregnancy, kidney disease, hormone exposure, diet, and other medicines. Those variables are reasons not to offer a personalized clearance estimate.
What the two-hour line cannot explain
Craving, dependence, withdrawal, cardiovascular response, and cessation outcomes do not follow directly from parent concentration decline. Neither does a cotinine test result. Repeated use can also create a pattern of overlapping exposures that is unlike the single normalized line.
The chart has one legitimate job: show the expected mathematical pace of a two-hour parent-nicotine half-life. Delivery systems, behavior, biomarkers, and clinical cessation support belong in their own evidence frameworks.
Reading this curve
HalfLifeDB uses 2 h as a representative input for Nicotine. In the simplified model, about 0.0% remains after 24 hours and about 3% remains after five half-lives, or roughly 10 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
stimulant context
Stimulant half-life estimates can shift with urine pH, enzyme activity, formulation, dose, and whether metabolites are measured separately.
- Alertness or subjective stimulation can end before modeled elimination.
- Sleep disruption and downstream effects are not represented by the curve.
- Formulation and route can change peak timing without changing the displayed model.
Nicotine timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 12.5% | Long-tail portion of the model |
| 12 h | 1.56% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.02% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Nicotine within the stimulant group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
Pharmacokinetics at a glance
| Representative half-life | 2 h |
|---|---|
| Curve type | Normalized, first-order decline |
Selection note: The linked clinical pharmacology review reports a roughly 2-hour elimination half-life for nicotine; cotinine persists much longer and is not modeled.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Full-text research Benowitz NL et al. Nicotine chemistry, metabolism, kinetics and biomarkers (2009).Comprehensive clinical pharmacology review supporting the roughly two-hour parent-nicotine half-life and the longer cotinine timeline.
- Official labeling DailyMed label: Nicotine polacrilex gum.Official nicotine-gum labeling included to show a medically described delivery system; not a model for smoking or every product.
- Identity record PubChem Compound Summary: Nicotine.Compound identity record; background only.
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the stimulant group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and profile review log before using the model for comparison.